|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 4
2017
Shi, W.; Jiang, T.; Nuciforo, P.; Hatzis, C.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Peña, L.; Loi, S.; Rosa, D. D.; Chia, S.; Wardley, A.; Ueno, T.; Rossari, J.; Eidtmann, H.; Armour, A.; Piccart-Gebhart, M.; Rimm, D. L.; Baselga, J. und Pusztai, L.
(2017):
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
In: Annals of Oncology, Bd. 28, Nr. 1: S. 128-135
2016
Prat, A.; Ortega, V.; Paré, L.; Galván, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; González, R.; Manso, L.; Martínez, J.; Llombart, A.; Peña, L. de la; di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J. und Cortés, J.
(2016):
Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study.
In: Cancer Research, Bd. 76
Pusztai, L.; Shi, W.; Jiang, T.; Nuciforo, P.; Holmes, E.; Harbeck, N.; Sotiriou, C.; Rimm, D.; Hatzis, C.; Pena, L. de la; Armour, A.; Piccart-Gebhart, M. und Baselga, J.
(2016):
Whole exome sequencing of pre-treatment biopsies from the neoALTTO trial to identify DNA aberrations associated with response to HER2-targeted therapies.
In: Cancer Research, Bd. 76
Wuerstlein, R.; Prat, A.; Ortega, V; Pare, L.; Galvan, P.; Nuciforo, P.; Oliverira, M.; Amillano, K.; Lopez, R.; Lluch, A.; Morales, S.; Gonzales, R.; Manso, L.; Martinez, J.; Llombart, A.; Pena, L. de la; Di Cosimo, S.; Rubio, I; Baselga, J.; Cortes, J. und Harbeck, N.
(2016):
Efficacy and gene expression results from SOLTI1007, a phase II study evaluating neoadjuvant eribulin in hormone receptor (HR)-positive/HER2-negative breast cancer.
In: Oncology Research and Treatment, Bd. 39: S. 182-183